361 related articles for article (PubMed ID: 32194562)
21. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
[TBL] [Abstract][Full Text] [Related]
22. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters.
Skiljevic D; Bonaci-Nikolic B; Brasanac D; Nikolic M
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):523-529. PubMed ID: 27557471
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in cutaneous lupus.
Maz MP; Martens JWS; Hannoudi A; Reddy AL; Hile GA; Kahlenberg JM
J Autoimmun; 2022 Oct; 132():102865. PubMed ID: 35858957
[TBL] [Abstract][Full Text] [Related]
25. Expression pattern of tissue-resident memory T cells in cutaneous lupus erythematosus.
Gu HJ; Song S; Roh JY; Jung Y; Kim HJ
Lupus; 2021 Aug; 30(9):1427-1437. PubMed ID: 34013817
[TBL] [Abstract][Full Text] [Related]
26. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus.
Robinson ES; Werth VP
Cytokine; 2015 Jun; 73(2):326-34. PubMed ID: 25767072
[TBL] [Abstract][Full Text] [Related]
27. Immunostimulatory Endogenous Nucleic Acids Perpetuate Interface Dermatitis-Translation of Pathogenic Fundamentals Into an
Braegelmann C; Fetter T; Niebel D; Dietz L; Bieber T; Wenzel J
Front Immunol; 2020; 11():622511. PubMed ID: 33505404
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.
Wenzel J
Nat Rev Rheumatol; 2019 Sep; 15(9):519-532. PubMed ID: 31399711
[TBL] [Abstract][Full Text] [Related]
29. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus.
Zahn S; Rehkämper C; Kümmerer BM; Ferring-Schmidt S; Bieber T; Tüting T; Wenzel J
J Invest Dermatol; 2011 Jan; 131(1):133-40. PubMed ID: 20720564
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
31. Role of neutrophils in cutaneous lupus erythematosus.
Yamamoto T
J Dermatol; 2024 Feb; 51(2):180-184. PubMed ID: 38009863
[TBL] [Abstract][Full Text] [Related]
32. Treatment of cutaneous lupus erythematosus: current approaches and future strategies.
Shi H; Gudjonsson JE; Kahlenberg JM
Curr Opin Rheumatol; 2020 May; 32(3):208-214. PubMed ID: 32141953
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.
Zhang YP; Wu J; Han YF; Shi ZR; Wang L
Autoimmun Rev; 2017 Jul; 16(7):735-742. PubMed ID: 28483542
[TBL] [Abstract][Full Text] [Related]
34. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus.
Wenzel J; Henze S; Wörenkämper E; Basner-Tschakarjan E; Sokolowska-Wojdylo M; Steitz J; Bieber T; Tüting T
J Invest Dermatol; 2005 Jun; 124(6):1241-8. PubMed ID: 15955100
[TBL] [Abstract][Full Text] [Related]
35. Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus.
Erazo-Martínez V; Tobón GJ; Cañas CA
Autoimmun Rev; 2023 Feb; 22(2):103262. PubMed ID: 36563771
[TBL] [Abstract][Full Text] [Related]
36. The deposition of anti-DNA IgG contributes to the development of cutaneous lupus erythematosus.
Dong Y; Zhang Y; Xia L; Wang P; Chen J; Xu M; Liu X; Xia Y
Immunol Lett; 2017 Nov; 191():1-9. PubMed ID: 28899632
[TBL] [Abstract][Full Text] [Related]
37. The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition.
Pietschke K; Holstein J; Meier K; Schäfer I; Müller-Hermelink E; Gonzalez-Menendez I; Quintanilla-Martinez L; Ghoreschi FC; Solimani F; Ghoreschi K
Exp Dermatol; 2021 Feb; 30(2):262-270. PubMed ID: 33113249
[TBL] [Abstract][Full Text] [Related]
38. Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus.
Vazquez T; Patel J; Kodali N; Diaz D; Bashir MM; Chin F; Keyes E; Sharma M; Sprow G; Grinnell M; Dan J; Werth VP
J Invest Dermatol; 2024 Jun; 144(6):1262-1272.e7. PubMed ID: 38086428
[TBL] [Abstract][Full Text] [Related]
39. Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus.
Freutel S; Gaffal E; Zahn S; Bieber T; Tüting T; Wenzel J
Lupus; 2011 Oct; 20(12):1300-4. PubMed ID: 21844117
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
